On Saturday, February 4, Team Veristat joined the battle against rare cancers at the 2017 Cycle for Survival event! Team Veristat had 14 riders at the Boston, MA event, including 2 colleagues from our UK office. Our team surpassed our goal of raising over $25,000 to fund rare cancer research!
Veristat Participates in Cycle for Survival 2017 and Raises over $25,000 to Fund Rare Cancer Research
February 23, 2017
January 23, 2017
One of the many perks at Veristat is that employees are encouraged to take a paid Day of Service every year to spend time volunteering and giving back to their surrounding community. We believe that part of making a difference in the world means making the time to help others.
January 5, 2017
For anyone who follows this blog with even moderate consistency, it is probably clear that Veristat is a growing organization. It is hopefully just as apparent that we are a group who tremendously values and fiercely protects our culture.
December 16, 2016
This Holiday Season, Veristat is continuing its tradition of participating in the Movement to Beat Rare Cancers!
On behalf of all of our clients, Veristat has made a $12,500 donation to one of the many organizations that we supported this year and will support in 2017, Cycle for Survival.
December 15, 2016
Read more about this and the discussions that you missed at the MassBio Forum on Adaptive Designs in Clinical Research that took place last month.
Just last week, in the midst of the daily chaos of building new clinical trial databases, working on impending regulatory submissions, holding project team meetings, and programing tables figures & listings, Veristat paused its operations for one day in order to reflect upon and celebrate its contributions to drug development.
At the 2016 Duke Industry Statistics Symposium, Dr. Robin Bliss, in collaboration with Dr. Jing Wang of Gilead Sciences, lead a discussion on “Biomarker-Driven Clinical Trial Designs for Precision Medicine.” Dr. Bliss highlighted two Adaptive Enrichment Clinical Trials performed by Veristat as case studies for how to select and execute an enrichment clinical trial design.
Veristat Acknowledged for its Rapid Growth on the Inc. 5000 List of America’s Fastest-Growing Private Companies
August 17, 2016
Veristat Continues To Be Recognized for Its Positive Impact & Company Growth
Today we announced that we have been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.
An adaptive design is a clinical trial design that allows adaptations or modifications to aspects of the trial after its initiation without undermining the validity and integrity of the trial. An adaptive design consists of multiple stages. At each stage, data analyses are conducted and adaptations take place based on updated information to maximize the probability of success of a trial.
July 14, 2016
If you're reading this as a biostatistician or clinical trial professional, you know that the pharmaceutical industry is shifting from classical to adaptive clinical trial design in an effort to reduce NDA failure rate, lower the cost of research and development, and expedite the precision medicine movement. As a member of the Talent & Culture team at Veristat (a CRO), I spend a great deal of time speaking with people like yourself, many of whom are potential candidates excited about the opportunity to work at a company where they may get exposure to an adaptive design trial. Realizing the consistency across these conversations, I have begun wondering if their interest in adaptive designs is a result of it being a current trends, or if it is because adaptive design truly offers increased efficiencies. As a result, I have spent some time research when adaptive design might not be right for a clinical trial and have found two articles that discuss when it is appropriate to use them.